Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Neoadjuvant Study Evaluating Capivasertib Plus Fulvestrant vs Fulvestrant in Patients With Primary High-risk Lobular Breast Cancer- LOBSTER

NCT06607757 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT06607757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06607757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Neoadjuvant Study Evaluating Capivasertib Plus Fulvestrant vs Fulvestrant in Patients With Primary High-risk Lobular Breast Cancer- LOBSTER
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
December 4, 2024
Completion date
August 31, 2026
Enrollment
120 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

ccca assessed by ki67 drop below <2.7% from baseline